Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Contineum Therapeutics, Inc.CTNM · Entity 5311 | General Counsel and Corp Sec | January 30, 2026 | January 30, 2026 |
| Tyra Biosciences, Inc.TYRA · Entity 4680 | General Counsel and Secretary | March 01, 2022 | March 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Contineum Therapeutics, Inc.
Report date January 30, 2026 · Filed January 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.26 · Expires 2036-01-29 | Direct | 206,411 |
Reported balance
After 2026-01-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-30 · Grant · Acquired 206,411 · Balance 206,411 F1: Options granted under the Issuer's 2024 Equity Incentive Plan. The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: Options granted under the Issuer's 2024 Equity Incentive Plan. The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's continuous service.
Tyra Biosciences, Inc.
Report date March 01, 2022 · Filed March 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2021-03-09 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-03-01 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: 1/48th of the shares subject to the option vest monthly following February 26, 2021, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.75 · Expires 2031-06-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-03-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: 25% of the shares subject to the option shall vest on March 5, 2022, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.15 · Expires 2031-11-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-03-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: 1/48th of the shares subject to the option vest monthly following November 2, 2021, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.15 · Expires 2031-11-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-03-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: The option vests based on achievement of a performance objective. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.15 · Expires 2031-11-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-03-01 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F4: The option vests based on achievement of a performance objective. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option vest monthly following February 26, 2021, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
F2: 25% of the shares subject to the option shall vest on March 5, 2022, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
F3: 1/48th of the shares subject to the option vest monthly following November 2, 2021, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
F4: The option vests based on achievement of a performance objective.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 30, 2026 Filed Jan 30, 2026 21:59 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 206,411 | $0.00 Strike: $14.26 | $0.00 |
DisclosureSEC source: 0001437749-26-002579 · rdgdoc.xml · derivative · entry 1 Healy John Stephen · CIK 0001908071 · General Counsel and Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,411 Underlying: Class A Common Stock · 206,411 shares Expires 2036-01-29 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan. The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's continuous service. Read SEC document |
| January 31, 2025 Filed Jan 31, 2025 21:41 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 63,589 | $0.00 Strike: $9.79 | $0.00 |
DisclosureSEC source: 0001437749-25-002436 · rdgdoc.xml · derivative · entry 1 Healy John Stephen · CIK 0001908071 · General Counsel and Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,589 Underlying: Class A Common Stock · 63,589 shares Expires 2035-01-30 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan. 25% of the option shares vest on January 1, 2026, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service. Read SEC document |
| June 03, 2024 Filed Jun 3, 2024 21:46 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 160,000 | $0.00 Strike: $15.73 | $0.00 |
DisclosureSEC source: 0001437749-24-019086 · rdgdoc.xml · derivative · entry 1 Healy John Stephen · CIK 0001908071 · General Counsel and Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Class A Common Stock · 160,000 shares Expires 2034-06-02 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan. 25% of the option shares vest on June 3, 2025, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.